Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28110239 | 0.84 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL15668222 | 0.82 | MAPT (0.50) | NPC1RAB9ATLR9SMN1; SMN2MAPT | |
| SCHEMBL27985386 | 0.81 | MEN1 (0.52) | NPC1RAB9ASMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL27160228 | 0.80 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL15668407 | 0.79 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28110839 | 0.77 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2ADORA3ADORA1 | |
| SCHEMBL4905327 | 0.76 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL28024203 | 0.76 | RAB9A (0.47) | NPC1RAB9ATLR9SMN1; SMN2MAPT | |
| SCHEMBL15668562 | 0.75 | EGFR (0.51) | NPC1RAB9ATLR9SMN1; SMN2MAPT | |
| SCHEMBL15668317 | 0.74 | CYP1A2 (0.48) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273743-B2 | N-(4-chloro-3-(quinoxalin-3-yl)phenyl)-3,5-dimethoxybenzamide; for treating malignancies | CURIS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1745041-B1 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | GENENTECH INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | GENENTECH, INC. | 2008-10-23 | — | — | US | disclosed |
| EP-1745041-A2 | QUINOXALINE INHIBITORS OF THE HEDGEHOG SIGNALLING PATHWAY | Genentech, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006078283-A2 | QUINOXALINE INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261989-A1 | Quinoxaline Inhibitors of the Hedgehog Signalling | SHH, NR4A2, NR4A3 | NPC1 2120/4885RAB9A 2425/4885TLR9 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.